[
  {
    "path": "hema/07-29-2022/",
    "title": "Fri Jul 29 2022",
    "description": "63 articles - From Friday Jul 22 2022 to Friday Jul 29 2022",
    "author": [],
    "date": "2022-07-29",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nLetters&Replies\r\nOthers\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#blhprraiex .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#blhprraiex .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#blhprraiex .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#blhprraiex .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#blhprraiex .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#blhprraiex .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#blhprraiex .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#blhprraiex .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#blhprraiex .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#blhprraiex .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#blhprraiex .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#blhprraiex .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#blhprraiex .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#blhprraiex .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#blhprraiex .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#blhprraiex .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#blhprraiex .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#blhprraiex .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#blhprraiex .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#blhprraiex .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#blhprraiex .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#blhprraiex .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#blhprraiex .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#blhprraiex .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#blhprraiex .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#blhprraiex .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#blhprraiex .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#blhprraiex .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#blhprraiex .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#blhprraiex .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#blhprraiex .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#blhprraiex .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#blhprraiex .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#blhprraiex .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#blhprraiex .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Haematologica\r\n    Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel.\r\ne., thrombotic risk factors and risk stratification, primary thromboprophylaxis, management of acute thrombotic events, and secondary thromboprophylaxis. The issued recommendations may assist hematologists in minimizing the risk of thrombosis and guarantee adherence to treatment in patients with MM candidates to active treatment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#pmfnzibxec .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#pmfnzibxec .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pmfnzibxec .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#pmfnzibxec .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#pmfnzibxec .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#pmfnzibxec .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pmfnzibxec .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#pmfnzibxec .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#pmfnzibxec .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#pmfnzibxec .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#pmfnzibxec .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#pmfnzibxec .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#pmfnzibxec .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#pmfnzibxec .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#pmfnzibxec .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#pmfnzibxec .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#pmfnzibxec .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#pmfnzibxec .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#pmfnzibxec .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#pmfnzibxec .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#pmfnzibxec .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#pmfnzibxec .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#pmfnzibxec .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#pmfnzibxec .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pmfnzibxec .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#pmfnzibxec .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pmfnzibxec .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#pmfnzibxec .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#pmfnzibxec .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#pmfnzibxec .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#pmfnzibxec .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#pmfnzibxec .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#pmfnzibxec .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#pmfnzibxec .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#pmfnzibxec .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood Adv\r\n    Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis.\r\nFindings should be interpreted with caution given high risk of bias in many studies. There is a clear need for high-quality contemporary trials to establish the effectiveness of different approaches to prevent infections.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#krtrpzpkjs .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#krtrpzpkjs .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#krtrpzpkjs .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#krtrpzpkjs .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#krtrpzpkjs .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#krtrpzpkjs .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#krtrpzpkjs .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#krtrpzpkjs .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#krtrpzpkjs .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#krtrpzpkjs .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#krtrpzpkjs .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#krtrpzpkjs .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#krtrpzpkjs .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#krtrpzpkjs .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#krtrpzpkjs .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#krtrpzpkjs .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#krtrpzpkjs .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#krtrpzpkjs .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#krtrpzpkjs .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#krtrpzpkjs .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#krtrpzpkjs .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#krtrpzpkjs .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#krtrpzpkjs .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#krtrpzpkjs .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#krtrpzpkjs .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#krtrpzpkjs .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#krtrpzpkjs .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#krtrpzpkjs .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#krtrpzpkjs .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#krtrpzpkjs .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#krtrpzpkjs .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#krtrpzpkjs .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#krtrpzpkjs .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#krtrpzpkjs .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#krtrpzpkjs .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.\r\nNo significant between group differences were observed. Patients with B-cell malignancies have inferior humoral responses against SARS-CoV-2 and booster dose enhances the NAb response in a proportion of these patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D mutated non-small cell lung cancer.\r\n KRAS G12D lung cancers harbor distinct clinical, genomic, and immunologic features compared to other KRAS mutated lung cancers and worse outcomes to PD-(L)1 blockade. Drug development for KRAS G12D lung cancers will have to take these differences into account.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Avapritinib for Advanced Systemic Mastocytosis.\r\nThe phase I EXPLORER and phase II PATHFINDER trials demonstrated that avapritinib can elicit complete and durable clinical responses, and molecular remission of KIT D816V. Key management challenges relate to the complex mutational landscape of AdvSM, often found with an associated hematologic neoplasm.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nErythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis.\r\nFinally, by molecular profiling, we reveal the heterogeneity of EBI macrophages by Cellular Indexing of Transcriptome and Epitopes (CITE)-sequencing of mouse bone marrow EBIs at baseline and after Epo-stimulation in vivo and provide a searchable, online viewer of this data characterizing the macrophage subsets serving as hematopoietic niches. Taken together, our findings demonstrate that EBIs serve a dual role as niches for terminal erythropoiesis and granulopoiesis and the central macrophages adapt to optimize production of red blood cells or neutrophils.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGab2-MALT1 Axis Regulates Thromboinflammation and Deep Vein Thrombosis.\r\nOverall, our data reveal a previously unrecognized role of the Gab2-MALT1 axis in thromboinflammation. Targeting the Gab2-MALT1 axis with MALT1 inhibitors may become an effective strategy to treat DVT by suppressing thromboinflammation without inducing bleeding complications.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLoss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness.\r\nDeletion of Sphk2 increases hypoxic responses by stabilizing the HIF1a protein to upregulate PDK3, a glycolysis checkpoint protein for HSC quiescence, which subsequently enhances the function of HSCs by improving their metabolic fitness;  specifically, it enhances anaerobic glycolysis but suppresses mitochondrial oxidative phosphorylation and generation of reactive oxygen species. Overall, targeting Sphk2 to enhance the metabolic fitness of HSCs is a promising strategy to expand and rejuvenate functional HSCs.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProphylactic administration of HPA-1a-specific antibodies prevents fetal/neonatal alloimmune thrombocytopenia in mice.\r\nHPA-1a-negative female mice treated prophylactically with anti-HPA-1a antibody prior to exposure to HPA-1a-positive platelets gave birth to HPA-1a-positive pups with significantly improved platelet counts and no bleeding symptoms. These preclinical data establish both the potential and threshold exposure targets for prophylactic treatment with HPA-1a-specific antibodies for the prevention of FNAIT in humans.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia.\r\nPML-RARA-initiated AML samples displayed a unique phosphorylation signature, and TP53-mutant samples showed abundant phosphorylation of serine-183 on TP53 itself. This publicly available database will serve as a foundation for further investigations of protein dysregulation in AML pathogenesis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nT-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.\r\nOur data demonstrate the relevance of T-cell exhaustion in bispecific antibody therapy and highlight that T cells can be functionally and transcriptionally rejuvenated with TFIs. In view of the growing number of bispecific molecules being evaluated in clinical trials, our findings emphasize the need to consider and evaluate TFIs in application schedules to improve clinical outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis.\r\nComparison of reduced-intensity HCT to non-HCT showed no statistically significant difference in any of the above endpoints. In conclusion, adult patients with Ph+ ALL who achieved CMR within 90 days of starting treatment did not derive a survival benefit from allo-HCT in CR1 in this retrospective study.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Cerebral vascular injury in transplant-associated thrombotic microangiopathy.\r\nIn summary, our study confirms that TA-TMA involves the brains of recipients of HCT and is associated with an increased incidence of neurologic symptoms. Based on these findings, we propose that patients with low- or moderate-risk TA-TMA who develop neurologic complications should be considered for TA-TMA-directed therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDevelopment and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument.\r\nThe HHT-QoL score correlated negatively with PROMIS Discretionary Social Activities (r = -0.65) and Social Roles (r = -0.68) and positively correlated with PROMIS Emotional Distress (r = 0.51). In conclusion, the 4-item HHT-QoL instrument provides valuable insight and may be a useful addition to future clinical research in HHT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDoxorubicin Pharmacokinetics and Toxicity in Patients with Aggressive Lymphoma and Hepatic Impairment.\r\nAlthough toxicity was greater on cycle 1, the adverse effects were managed safely. These results show that empiric dose reductions of continuous infusion doxorubicin may not be necessary in patients with elevated bilirubin.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGender and Early-career Faculty Disparities in Hematology and Oncology Board Review Lecture Series.\r\nA positive trend in the participation of women was found at al board review conferences across the studied period. Our data suggest that women and early-career faculty participation in hematology and oncology board review series is inadequate.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.\r\nIn conclusion, activating STAT3 mutations are common in ENKTLs and are associated with increased CD30 expression. MYC overexpression is, at least in part, associated with deleterious BCOR mutations, and this BCOR-MYC linkage may have prognostic significance, underscoring the potential utility of immunohistochemistry for MYC in risk stratification of patients with ENKTL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGranulocytic myeloid-derived suppressor cells to prevent and treat murine immune-mediated bone marrow failure.\r\nB10 AA model. Our results demonstrate that G-MDSC eradication and therapeutic efficacy are immune context-dependent.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImproving NK Cell Function in Multiple Myeloma with NKTR-255, a Novel Polymer-Conjugated Human IL-15.\r\nFinally, we observed that combination of NKTR-255 with the anti-CD38 antibody, daratumumab, was effective against MM cells in vitro and in vivo. Taken together, our data suggest a significant impact of NKTR-255 in inducing NK cell function against MM cells with important translational implications.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSpatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma.\r\nClinical significance of imaging-guided biopsies of lesions was demonstrated by detection of monoclonal PC in patients without measurable residual disease (MRD) in aspirates from the iliac crest as well as identification of secondary primary malignancies in MRD-negative patients. Furthermore, site-specific clones with different drug susceptibilities and genetically defined high-risk features were detected by our workflow.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnalysis of rare driving events in pediatric acute myeloid leukemia.\r\nIn 75% of patients an aberration with a prognostic impact could be detected. Therefore, we suggest these techniques need to become standard of care in diagnostics.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGetting (T-cells) ENGaged.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHypercortisolemic Cushing's patients possess a distinct class of hematopoietic progenitor cells leading to erythrocytosis.\r\nCollectively, these results indicate that chronic exposure to excess glucocorticoids in vivo leads to erythrocytosis by generating erythroid progenitor cells with a constitutively active GR. Although remission rescues the erythrocytosis and the phenotype of the circulating CD34+ cells, a memory of other prior changes is maintained in remission.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImproving the anti-acute myeloid leukemia activity of CD123-specific Engager T cells by MyD88 and CD40 costimulation.\r\nOur work highlights the need for both toll-like receptor (TLR) pathway activation via MyD88 and provision of costimulation via CD40 to consistently enhance the antitumor activity of CD123. ENG T cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLow-intensity induction in acute myeloid leukemia. Always in the patients' best interest?\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMinnesota acute GvHD risk score predicts survival at onset of GvHD after PTCy prophylaxis.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?\r\nIn addition to these approaches, it is of interest to identify higher-resolution actionable biomarkers that can predict treatment responses and toxicity, and inform personalized treatment decisions. Here, we discuss the current status of PI3K inhibitors in CLL, factors limiting the use of currently approved PI3K inhibitors in CLL, current strategies to overcome these limitations, and where to go next.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe effects on erythropoiesis of chronic glucorticoid stimulation in Cushing's syndrome.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTime spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens.\r\nPDH did not differ between therapy groups (adjusted mean, AZA+VEN: 0.68;  AZA monotherapy: 0.66;  p=0.64) or between disease risk categories (p=0.34). Compared to AZA monotherapy, patients receiving AZA+VEN had longer clinic visits (median minutes: 127.9 vs 112.9, p.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype.\r\nhUC-EVs-ATO enhanced the alleviation of aGVHD severity in mice compared with ATO and hUC-EVs without weakening GVL activity. hUC-EVs-ATO promoted M1 to M2 polarization via the mTOR-autophagy pathway. hUC-EVs-ATO could be a potential therapeutic approach in aGVHD after allo-HSCT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLancet Haematol\r\n    Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.\r\nExtractEHR-based adverse event ascertainment can improve reporting of laboratory adverse events in clinical trials. Funding US National Institutes of Health, St Baldrick's Foundation, and Alex's Lemonade Stand Foundation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.\r\nWe conclude that the addition of selinexor to standard chemotherapy does negatively affect the therapeutic outcome of elderly AML patients. (Netherlands Trial Registry number NL5748 (NTR5902), ).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOverall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.\r\nWeek 24 TI response in JAKi-naÃ¯ve, momelotinib-randomized patients was associated with improved OS in univariate (HR=0.323;  p<0.0001) and multivariate (HR=0.311;  p<0.0001) analyses. These findings underscore the importance of achieving or maintaining TI in myelofibrosis, supporting the clinical relevance of momelotinib's pro-erythropoietic mechanism of action, and potentially informing treatment decision-making.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPredictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia.\r\nSplicing factors and RUNX1 somatic variants were detected exclusively at high-risk evolution;  DNMT3A, BCOR/L1 and ASXL1 were present in both. RUNX1, splicing factors and ASXL1 somatic mutations detected at 6 months after IST predicted high-risk evolution.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Current View on the Molecular Mechanisms Underlying Fibrin(ogen)-Dependent Inflammation.\r\nThis pathway is inhibited by another pathway induced by the interaction of ÃŸ15-42 with a putative endothelial receptor. In this review, we briefly describe the previously proposed molecular mechanisms underlying fibrin-dependent inflammation and their advantages/disadvantages and summarize our recent studies of the novel VLDL receptor-dependent pathway of leukocyte transmigration which plays an important role in fibrin-dependent inflammation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#umuwantxrq .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#umuwantxrq .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#umuwantxrq .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#umuwantxrq .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#umuwantxrq .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#umuwantxrq .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#umuwantxrq .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#umuwantxrq .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#umuwantxrq .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#umuwantxrq .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#umuwantxrq .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#umuwantxrq .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#umuwantxrq .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#umuwantxrq .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#umuwantxrq .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#umuwantxrq .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#umuwantxrq .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#umuwantxrq .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#umuwantxrq .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#umuwantxrq .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#umuwantxrq .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#umuwantxrq .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#umuwantxrq .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#umuwantxrq .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#umuwantxrq .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#umuwantxrq .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#umuwantxrq .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#umuwantxrq .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#umuwantxrq .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#umuwantxrq .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#umuwantxrq .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#umuwantxrq .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#umuwantxrq .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#umuwantxrq .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#umuwantxrq .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia: Past Discoveries and Future Directions.\r\nIn this review, we discuss the path to regulatory approval of azacitidine and decitabine, highlighting the substantial efforts that have been made to optimize the dosing schedule and administration of these drugs, including the development of new, oral formulations of both agents. We also review novel combination strategies that are being investigated in ongoing clinical trials for patients with MDS and AML, as well as efforts to expand the current indications of these agents.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    CD7 CAR: sword and shield.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFibrinolysis without intracranial hemorrhage.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGerman CARs keeping pace.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHLH: birds of a feather flock together.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNovel genotype-phenotype interaction in HIT.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe 2 faces of ERK2 in MPNs.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe tension rises in leukocyte extravasation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUncovering CD4+ T-cell exhaustion in B-ALL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer.\r\nUPR mt is conserved and activated in cancer in response to mitochondrial stress to maintain mitochondrial integrity and support tumor growth. In this review, we discuss how mitochondria become dysfunctional in cancer and highlight the tumor-promoting functions of key components of the UPR mt .\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLeukemia\r\n    Immune senescence in multiple myeloma-a role for mitochondrial dysfunction?\r\nA link between cellular mitochondrial dysfunction and the acquisition of an abnormal immune phenotype has recently been described and has widespread physiological consequence beyond the impact on the immune system. Here we outline our current understanding of normal immune aging, describe the mechanism of immunometabolic dysfunction in accelerating this process, and propose the role these processes are playing in the pathogenesis of MM.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#mxxzzhqafd .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#mxxzzhqafd .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mxxzzhqafd .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#mxxzzhqafd .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#mxxzzhqafd .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#mxxzzhqafd .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mxxzzhqafd .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#mxxzzhqafd .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#mxxzzhqafd .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#mxxzzhqafd .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#mxxzzhqafd .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#mxxzzhqafd .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#mxxzzhqafd .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#mxxzzhqafd .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#mxxzzhqafd .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#mxxzzhqafd .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#mxxzzhqafd .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#mxxzzhqafd .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#mxxzzhqafd .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#mxxzzhqafd .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#mxxzzhqafd .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#mxxzzhqafd .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#mxxzzhqafd .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#mxxzzhqafd .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mxxzzhqafd .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#mxxzzhqafd .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mxxzzhqafd .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#mxxzzhqafd .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#mxxzzhqafd .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#mxxzzhqafd .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#mxxzzhqafd .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#mxxzzhqafd .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#mxxzzhqafd .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#mxxzzhqafd .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#mxxzzhqafd .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Characteristics and Outcome of Adults With Severe Autoimmune Hemolytic Anemia Admitted to the Intensive Care Unit: Results From A Large French Observational Study.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHemophagocytic Lymphohistiocytosis secondary to CAR-T cells: Update from the FDA and Vizient databases.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPredicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRacial differences as predictors of outcomes in young patients with multiple myeloma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTherapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOthers\r\nall remaining publications eg case reports, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#hknarywiqw .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#hknarywiqw .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#hknarywiqw .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#hknarywiqw .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#hknarywiqw .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#hknarywiqw .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#hknarywiqw .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#hknarywiqw .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#hknarywiqw .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#hknarywiqw .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#hknarywiqw .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#hknarywiqw .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#hknarywiqw .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#hknarywiqw .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#hknarywiqw .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#hknarywiqw .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#hknarywiqw .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#hknarywiqw .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#hknarywiqw .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#hknarywiqw .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#hknarywiqw .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#hknarywiqw .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#hknarywiqw .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#hknarywiqw .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#hknarywiqw .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#hknarywiqw .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#hknarywiqw .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#hknarywiqw .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#hknarywiqw .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#hknarywiqw .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#hknarywiqw .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#hknarywiqw .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#hknarywiqw .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#hknarywiqw .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#hknarywiqw .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    A case of chronic neutrophilic leukaemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFlow and ICAM1 initiate leukocyte extravasation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReed-Sternberg-like cells in a case of follicular lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    A starting point for the phenotypic classification of pulmonary chronic graft-versus-host disease.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCAR T-cell therapy for mantle cell lymphoma with central nervous system relapse.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPediatric patient with fibrinogen Villeurbanne II presenting with an unprovoked portal vein thrombosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nWhite blood cell ranges and frequency of neutropenia by Duffy genotype status.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Reducing toxic waste: improving toxicity capture in childhood cancer.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-07-29T08:19:28-04:00",
    "input_file": {}
  },
  {
    "path": "hema/07-22-2022/",
    "title": "Fri Jul 22 2022",
    "description": "82 articles - From Friday Jul 15 2022 to Friday Jul 22 2022",
    "author": [],
    "date": "2022-07-22",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nLetters&Replies\r\nOthers\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#gtvouowmjm .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#gtvouowmjm .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#gtvouowmjm .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#gtvouowmjm .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#gtvouowmjm .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#gtvouowmjm .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#gtvouowmjm .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#gtvouowmjm .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#gtvouowmjm .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#gtvouowmjm .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#gtvouowmjm .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#gtvouowmjm .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#gtvouowmjm .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#gtvouowmjm .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#gtvouowmjm .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#gtvouowmjm .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#gtvouowmjm .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#gtvouowmjm .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#gtvouowmjm .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#gtvouowmjm .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#gtvouowmjm .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#gtvouowmjm .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#gtvouowmjm .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#gtvouowmjm .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#gtvouowmjm .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#gtvouowmjm .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#gtvouowmjm .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#gtvouowmjm .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#gtvouowmjm .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#gtvouowmjm .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#gtvouowmjm .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#gtvouowmjm .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#gtvouowmjm .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#gtvouowmjm .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#gtvouowmjm .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Haematologica\r\n    Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel.\r\ne., thrombotic risk factors and risk stratification, primary thromboprophylaxis, management of acute thrombotic events, and secondary thromboprophylaxis. The issued recommendations may assist hematologists in minimizing the risk of thrombosis and guarantee adherence to treatment in patients with MM candidates to active treatment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#pigepafyes .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#pigepafyes .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pigepafyes .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#pigepafyes .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#pigepafyes .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#pigepafyes .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pigepafyes .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#pigepafyes .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#pigepafyes .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#pigepafyes .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#pigepafyes .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#pigepafyes .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#pigepafyes .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#pigepafyes .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#pigepafyes .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#pigepafyes .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#pigepafyes .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#pigepafyes .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#pigepafyes .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#pigepafyes .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#pigepafyes .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#pigepafyes .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#pigepafyes .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#pigepafyes .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pigepafyes .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#pigepafyes .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#pigepafyes .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#pigepafyes .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#pigepafyes .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#pigepafyes .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#pigepafyes .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#pigepafyes .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#pigepafyes .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#pigepafyes .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#pigepafyes .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#ihewilzqyo .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#ihewilzqyo .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ihewilzqyo .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#ihewilzqyo .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#ihewilzqyo .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#ihewilzqyo .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ihewilzqyo .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#ihewilzqyo .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#ihewilzqyo .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#ihewilzqyo .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#ihewilzqyo .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#ihewilzqyo .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#ihewilzqyo .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#ihewilzqyo .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#ihewilzqyo .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#ihewilzqyo .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#ihewilzqyo .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#ihewilzqyo .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#ihewilzqyo .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#ihewilzqyo .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#ihewilzqyo .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#ihewilzqyo .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#ihewilzqyo .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#ihewilzqyo .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ihewilzqyo .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#ihewilzqyo .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ihewilzqyo .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#ihewilzqyo .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#ihewilzqyo .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#ihewilzqyo .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#ihewilzqyo .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#ihewilzqyo .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#ihewilzqyo .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#ihewilzqyo .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#ihewilzqyo .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Ann Oncol\r\n    Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.\r\n We demonstrate that baseline ARG levels predict ICI response. Plasma ARG quantification may therefore represent an attractive biomarker to tailor novel therapeutic regimens targeting the ARG pathway in combination with ICIs.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nToripalimab (anti-PD-1) versus High-Dose Interferon-a2b as Adjuvant Therapy in Resected Mucosal Melanoma: A Phase II Randomized Trial.\r\n Toripalimab showed a similar RFS and a more favorable safety profile than HDI, both better than historical data, suggesting that toripalimab might be the better treatment option. However, additional translational studies and better treatment regimens are still warranted to improve the clinical outcome of MM.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Developing a Classification of Hematologic Neoplasms in the Era of Precision Medicine.\r\nA collaborative clinico-pathologic review process will provide a mechanism to update pathologic and genomic criteria within a clinical context. An interactive web-based portal would make the classification more immediately available to the scientific community, while providing accessory features enabling practical application of diagnostic, prognostic, and predictive information.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEpigenetic regulator genes direct lineage switching in MLL/AF4 leukaemia.\r\nThe relapsed myeloid phenotype is recurrently associated with the altered expression, splicing or mutation of chromatin modifiers, including CHD4 coding for the ATPase/helicase of the nucleosome remodelling and deacetylation complex, NuRD. Perturbation of CHD4 alone or in combination with other mutated epigenetic modifiers induces myeloid gene expression in MLL/AF4-positive cell models indicating that lineage switching in MLL/AF4 leukaemia is driven and maintained by disrupted epigenetic regulation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nErythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis.\r\nFinally, by molecular profiling, we reveal the heterogeneity of EBI macrophages by Cellular Indexing of Transcriptome and Epitopes (CITE)-sequencing of mouse bone marrow EBIs at baseline and after Epo-stimulation in vivo and provide a searchable, online viewer of this data characterizing the macrophage subsets serving as hematopoietic niches. Taken together, our findings demonstrate that EBIs serve a dual role as niches for terminal erythropoiesis and granulopoiesis and the central macrophages adapt to optimize production of red blood cells or neutrophils.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLoss Of COP9-Signalosome Genes At 2q37 Is Associated With IMiD Agent Resistance In Multiple Myeloma.\r\nThe COP9 signalosome is essential for maintenance of the CUL4-DDB1-CRBN E3 Ubiquitin Ligase. This region may represent a novel marker of IMiD resistance with clinical utility.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nModerate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial.\r\nMore than 60% of participants randomized to receive both exercise and desmopressin achieved normal (>50%) FVIII:C, 75- and 135-minutes into the study protocol.  NCT03379974;  NCT03136003.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPatient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.\r\nAxi-cel showed clinically meaningful improvements in QoL over SOC. Superior clinical outcomes and favorable patient experience with axi-cel should help inform treatment choices in second-line R/R LBCL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTargeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.\r\nPatient-derived AML-cells exhibited increased TRAIL-R1/2 and MHC-II expression upon MDM2-inhibition. In summary, we identified a targetable vulnerability of AML cells to allogeneic T-cell-mediated cytotoxicity, through restoration of p53-dependent TRAIL-R1/2 and MHC-II-production via MDM2-inhibition.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTicagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.\r\n: ClinicalTrials. gov NCT03615924.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVenetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1.\r\nIn summary, our results suggest that combined inhibition of FLT3/AXL potentiates venetoclax response in FLT3-wildtype AML by inducing MCL-1 degradation. Thus, the venetoclax-gilteritinib combination merits testing as potentially active regimen in high-risk AML patients with FLT3 wildtype.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.\r\nClinicalTrials. gov Identifier: NCT00988013.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCauses of Death in Low Grade B-Cell Lymphomas in the Rituximab Era: A Prospective Cohort Study.\r\nIn conclusions, the most common COD in LGBCLs in the first decade after diagnosis was for causes other than lymphoma. Progression or retreatment within the first 2 years of diagnosis was a strong predictor for risk of lymphoma-related death.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDefective RAB31-mediated megakaryocytic early endosomal trafficking of VWF, EGFR, and M6PR in RUNX1 deficiency.\r\nThere was loss of plasma membrane VWF in RUNX1- and RAB31- deficient megakaryocytic HEL cells, and RHD-iMKs These studies provide evidence that RAB31 is downregulated in RUNX1 haplodeficiency and regulates megakaryocytic vesicle trafficking of 3 major proteins with diverse biological roles. Early endosome defect and impaired vesicle trafficking is a potential mechanism for the -granule defects observed in RUNX1 deficiency.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDifferences in wild type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies.\r\nSupplementing FX into CSA had the effect of dampening FIX-WT activity relative to R338L-FIX activity, suggesting that FX impairs WT tenase formation to a greater extent than R338L-FIX tenase. Our data describe the scale of R338L-FIX assay discrepancies and provide insights into the causative mechanisms that will help establish best practices for the measurement of R338L-FIX activity in patients after gene therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDisparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.\r\nIn summary, Hispanic patients treated on CALGB 10403 did as well as NHWs and better than population estimates. Geographical misalignment between trial sites and disease epidemiology may partially explain the lower-than-expected enrollment of Hispanic AYA ALL patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIntraosseous delivery of platelet-targeted FVIII lentiviral vector in humanized NBSGW mice.\r\nMost importantly, IO delivery of G-F8-LV to humanized NBSGW mice produced persistent FVIII expression in human platelets after gene therapy, and the megakaryocytes differentiated from human CD34+ HSPCs isolated from LV-treated humanized mice showed up to 10.2% FVIII expression, indicating efficient transduction of self-regenerating human HSPCs. Collectively, these results indicate the long-term safety and efficacy of IO-LV gene therapy strategy for hemophilia A in a humanized model, adding further evidence to the feasibility of translating this method for clinical applications.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMembrane curvature and PS localize coagulation proteins to filopodia and retraction fibers of endothelial cells.\r\nOur results indicate that stressed or stimulated endothelial cells support prothrombinase activity localized to convex topological features at cell margins. These findings may relate to perivascular fibrin deposition in sepsis and inflammation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNeighborhood disadvantage, health status, and healthcare utilization after blood or marrow transplant: BMTSS report.\r\nIn BMT survivors, access to healthcare and health status are associated with area disadvantage. These findings may inform strategies to address long-term care coordination and retention for vulnerable survivors.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNK cell CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma.\r\nThese results suggest that NK cell exhaustion is already present by the time of myeloma diagnosis and likely contributes to the loss of immunological control of malignant plasma cells. Restoring NK cell function via immune directed therapies offers a route to restoring immunological control in multiple myeloma.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nQuality of Life, Psychological Distress, and Prognostic Perceptions in Caregivers of Patients with Multiple Myeloma.\r\nThe majority of caregivers of patients with MM report that knowing the patient's prognosis is extremely important and report that the oncologist told them that the patient was incurable. Nevertheless, a significant portion of caregivers believe that the patient's MM is curable.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.\r\nThe inhibitor incidence was 29.9%. All patients with temporarily decreased IR continuing on N8-GP dosing returned within the expected range and had no evident lack of efficacy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTotal marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide.\r\nFor patients treated with 2000 cGy, with a median follow-up duration of 12.3 months, 1-year relapse/progression, progression-free survival, and overall survival rates were 17%, 74%, and 83%, respectively. In conclusion, HaploHCT-TMLI with PTCy was safe and feasible in our high-risk patient population with promising outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.\r\nDegradation of BRD9 potentiated the effects of several chemotherapeutic agents and targeted therapies against AML, ALL, and MM. Our findings support further development of therapeutic targeting of BRD9, alone or combined with other agents, as a novel strategy for acute leukemias and MM.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLong-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.\r\nForty-nine patients died (9.5%), following an infection in 14 cases (2.7%), natural causes in 14 (2.7%), cardiovascular events in 13 (2.5%), a second neoplasm in 6 (1.2%), and progression of HCL in 2 cases (0.4%). Following treatment of HCL with 2CDA, 80% of patients are estimated to be alive 15 years after diagnosis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.\r\nOne-year non-relapse mortality and progression/relapse were 22% and 33% respectively. On multivariate analysis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nExtranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHistological, genetic characterization and follow-up of 130 patients with chronic triplenegative thrombocytosis.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHypercortisolemic Cushing's patients possess a distinct class of hematopoietic progenitor cells leading to erythrocytosis.\r\nCollectively, these results indicate that chronic exposure to excess glucocorticoids in vivo leads to erythrocytosis by generating erythroid progenitor cells with a constitutively active GR. Although remission rescues the erythrocytosis and the phenotype of the circulating CD34+ cells, a memory of other prior changes is maintained in remission.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImproved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data.\r\nThe relative benefit associated with CR1 and the relative detriment associated with relapse have decreased over this period;  while achieving CR1 and relapse from CR1 still have strong prognostic associations with outcomes, the magnitude of the association has decreased over time. Possible explanations for these patterns include higher CR rates with salvage therapies after relapse, more frequent use of hematopoietic cell transplant, and better supportive care.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInflammation in WaldenstrÃ¶m macroglobulinemia is associated with 6q deletion and need for treatment initiation.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLow-intensity induction in acute myeloid leukemia. Always in the patients' best interest?\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion.\r\nInstead, we identified a strong association between PDL1 expression and CHL MHC-II expression, TH recruitment, and enrichment of Th1 regulatory cells. These data suggest that a dominant effect of PDL1 expression in CHL may be T helper engagement and promotion of regulatory microenvironment rather than maintenance of exhaustion.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRHOA regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia.\r\nThis elevated IGFBP2 expression is confirmed in primary CML samples. Thus, we demonstrate one mechanism whereby RHOA-SRF-IGFBP2 signaling axis contributes to development of leukemia in cells expressing the p210 BCRABL1 fusion kinase.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe effects on erythropoiesis of chronic glucorticoid stimulation in Cushing's syndrome.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTime spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens.\r\nPDH did not differ between therapy groups (adjusted mean, AZA+VEN: 0.68;  AZA monotherapy: 0.66;  p=0.64) or between disease risk categories (p=0.34). Compared to AZA monotherapy, patients receiving AZA+VEN had longer clinic visits (median minutes: 127.9 vs 112.9, p.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis.\r\nThis study suggests that GPD1 may act as a novel tumor suppressor in bladder cancer. Pharmacological activation of GPD1 is a potential therapeutic approach for bladder cancer.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nhUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype.\r\nhUC-EVs-ATO enhanced the alleviation of aGVHD severity in mice compared with ATO and hUC-EVs without weakening GVL activity. hUC-EVs-ATO promoted M1 to M2 polarization via the mTOR-autophagy pathway. hUC-EVs-ATO could be a potential therapeutic approach in aGVHD after allo-HSCT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHypertension and incident cardiovascular events after next-generation BTKi therapy initiation.\r\nCollectively, these data suggest that hypertension may be a class effect of BTKi therapies and precedes major cardiotoxic events.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLancet Haematol\r\n    The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.\r\nFuture studies should explore the reasons behind these epidemiological transitions. Funding None.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.\r\nTP53 mutations on exons 5, 6 and 7 are predictors of progression and survival. Targeting mutant p53 by APR-246 is a promising therapeutic approach for DLBCL patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPARP14 is a novel target in STAT6 mutant follicular lymphoma.\r\nKnock-down of PARP14 or PARP-inhibition abrogated the STAT6 MUT gain-of-function phenotype. Thus, our results identify PARP14 as a novel therapeutic target in STAT6 MUT FL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia.\r\nMRD defined by this strategy provides relevant prognostic information and establishes aberrancies outside of cell populations with markers of immaturity as an independent risk feature. Our results imply that this strategy may provide the base for multicentric immunophenotypic MRD assessment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    The Platelet Lipidome Is Altered in Patients with COVID-19 and Correlates with Platelet Reactivity.\r\n  Taken together, this investigation provides the first exploration of the profound impact of infection on the human platelet lipidome, and reveals associations between the lipid composition of platelets and their reactivity. These results warrant further lipidomic research in other infections and disease states involving platelet pathophysiology.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#fogswknxgu .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#fogswknxgu .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fogswknxgu .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#fogswknxgu .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#fogswknxgu .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fogswknxgu .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fogswknxgu .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fogswknxgu .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#fogswknxgu .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#fogswknxgu .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#fogswknxgu .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#fogswknxgu .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fogswknxgu .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fogswknxgu .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#fogswknxgu .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#fogswknxgu .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fogswknxgu .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#fogswknxgu .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fogswknxgu .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fogswknxgu .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fogswknxgu .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fogswknxgu .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#fogswknxgu .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fogswknxgu .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fogswknxgu .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fogswknxgu .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fogswknxgu .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fogswknxgu .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#fogswknxgu .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#fogswknxgu .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#fogswknxgu .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#fogswknxgu .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#fogswknxgu .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#fogswknxgu .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#fogswknxgu .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    Antithrombin deficiency: no sugar, no diagnosis!\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBuckling up against COVID-19 after CAR T-cell therapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nGPIIb/IIIa-GPVI-commanded platelet patrol.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHLH: birds of a feather flock together.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIbrutinib frontline in young patients with CLL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIncorporating signaling dynamics into fate decision.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNovel genotype-phenotype interaction in HIT.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe tension rises in leukocyte extravasation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Emerging strategies to overcome resistance to third-generation EGFR inhibitors.\r\nIn view of resistance to third-generation inhibitors, understanding the intricate mechanisms of resistance will offer insight for the development of more advanced targeted therapies. In this review, we discuss the molecular mechanisms of resistance to third-generation EGFR inhibitors and review recent strategies for overcoming resistance, new challenges, and future development directions.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nExploring immunotherapy in colorectal cancer.\r\nClinical trials examining the effect of immune checkpoints are actively carried out, in order to produce long-lasting effects for mCRC patients. This review summarizes the treatment strategies for mCRC patients, discusses the mechanism and application of ICB in mCRC treatment, outlines the potential markers of the ICB efficacy, lists the key results of the clinical trials, and collects the recent basic research results, in order to provide a theoretical basis and practical direction for immunotherapy strategies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nMitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.\r\nHere, we review the most recent literature to summarize the molecular mechanisms underlying mitochondrial stress adaptation and their intricate connection with cancer drug resistance. In addition, an overview of the emerging strategies to target mitochondria for effectively overcoming chemoresistance is highlighted, with an emphasis on drug repositioning and mitochondrial drug delivery approaches, which may accelerate the application of mitochondria-targeting compounds for cancer therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTargeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.\r\nThis review focused on the discovery, structural modification, preclinical and clinical research of the above compounds from the perspective of medicinal chemistry. Based on this, the possible defects in MDM2 inhibitors in clinical development were analyzed to suggest that the multitarget strategy or targeted degradation strategy based on MDM2 has the potential to reduce the dose-dependent hematological toxicity of MDM2 inhibitors and improve their anti-tumor activity, providing certain guidance for the development of agents targeting the p53-MDM2 interaction.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nThe mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer.\r\nUPR mt is conserved and activated in cancer in response to mitochondrial stress to maintain mitochondrial integrity and support tumor growth. In this review, we discuss how mitochondria become dysfunctional in cancer and highlight the tumor-promoting functions of key components of the UPR mt .\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#bafxbyeywt .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#bafxbyeywt .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bafxbyeywt .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#bafxbyeywt .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#bafxbyeywt .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#bafxbyeywt .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bafxbyeywt .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#bafxbyeywt .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#bafxbyeywt .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#bafxbyeywt .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#bafxbyeywt .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#bafxbyeywt .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#bafxbyeywt .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#bafxbyeywt .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#bafxbyeywt .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#bafxbyeywt .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#bafxbyeywt .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#bafxbyeywt .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#bafxbyeywt .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#bafxbyeywt .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#bafxbyeywt .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#bafxbyeywt .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#bafxbyeywt .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#bafxbyeywt .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bafxbyeywt .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#bafxbyeywt .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bafxbyeywt .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#bafxbyeywt .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#bafxbyeywt .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#bafxbyeywt .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#bafxbyeywt .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#bafxbyeywt .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#bafxbyeywt .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#bafxbyeywt .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#bafxbyeywt .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Does Fetal Hemoglobin inhibit the malarial parasite Plasmodium falciparum?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEarly hydroxyurea use is neuroprotective in children with sickle cell anemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSpace anemia unexplained: Red blood cells seem to be space-proof.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Clonal Hematopoiesis Is Not Significantly Associated with Covid-19 Disease Severity.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nJ Hematol Oncol\r\n    Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.\r\nOnly primary refractory disease to first-line therapy predicted a higher probability of PP to ibrutinib (RR=3.77, 95% CI 1.15-12.33, p=0.03). In this largest study to date evaluating outcomes of R/R MZL treated with ibrutinib, we show that patients with primary refractory disease and those with PP on ibrutinib are very high-risk subsets and need to be prioritized for experimental therapies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\n\r\n\r\n\r\nOthers\r\nall remaining publications eg case reports, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#mmdeqabtyh .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#mmdeqabtyh .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mmdeqabtyh .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#mmdeqabtyh .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#mmdeqabtyh .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#mmdeqabtyh .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mmdeqabtyh .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#mmdeqabtyh .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#mmdeqabtyh .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#mmdeqabtyh .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#mmdeqabtyh .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#mmdeqabtyh .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#mmdeqabtyh .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#mmdeqabtyh .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#mmdeqabtyh .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#mmdeqabtyh .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#mmdeqabtyh .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#mmdeqabtyh .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#mmdeqabtyh .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#mmdeqabtyh .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#mmdeqabtyh .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#mmdeqabtyh .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#mmdeqabtyh .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#mmdeqabtyh .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mmdeqabtyh .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#mmdeqabtyh .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#mmdeqabtyh .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#mmdeqabtyh .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#mmdeqabtyh .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#mmdeqabtyh .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#mmdeqabtyh .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#mmdeqabtyh .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#mmdeqabtyh .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#mmdeqabtyh .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#mmdeqabtyh .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    AML risk models: where do we stand ?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAn unexpected finding during microscopy for urinary hemosiderin.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHuman Papilloma Virus Vaccine and VITT antibody induction.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInsane in the membrane: A case of hereditary spherocytic pyropoikilocytosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFlow and ICAM1 initiate leukocyte extravasation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReed-Sternberg-like cells in a case of follicular lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSecondary AML with MLL gene amplification.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Chronic inflammation persistence after regular blood transfusion therapy in sickle cell anemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCombined BCL2 and BTK Inhibition in CLL Demonstrates Efficacy after Monotherapy with Both Classes.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDiscovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLiver Fibrosis and its Response to Avapritinib in 2 Patients with Systemic Mastocytosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLow rate of subsequent malignant neoplasms following CAR T-cell therapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPhase 1/2 Study of Ixazomib with Cyclophosphamide and Dexamethasone (IxaCyD) in Newly Diagnosed AL Amyloidosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUnified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Improving the global reporting of multiple myeloma: a focus on low-income and middle-income countries.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-07-22T21:02:25-04:00",
    "input_file": {}
  },
  {
    "path": "hema/07-15-2022/",
    "title": "Fri Jul 15 2022",
    "description": "98 articles - From Friday Jul 08 2022 to Friday Jul 15 2022",
    "author": [],
    "date": "2022-07-15",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nLetters&Replies\r\nOthers\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#fxnhicoecs .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#fxnhicoecs .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fxnhicoecs .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#fxnhicoecs .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#fxnhicoecs .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fxnhicoecs .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fxnhicoecs .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fxnhicoecs .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#fxnhicoecs .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#fxnhicoecs .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#fxnhicoecs .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#fxnhicoecs .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fxnhicoecs .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#fxnhicoecs .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#fxnhicoecs .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#fxnhicoecs .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#fxnhicoecs .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#fxnhicoecs .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fxnhicoecs .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fxnhicoecs .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#fxnhicoecs .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#fxnhicoecs .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#fxnhicoecs .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#fxnhicoecs .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fxnhicoecs .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fxnhicoecs .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#fxnhicoecs .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#fxnhicoecs .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#fxnhicoecs .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#fxnhicoecs .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#fxnhicoecs .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#fxnhicoecs .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#fxnhicoecs .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#fxnhicoecs .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#fxnhicoecs .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Ann Oncol\r\n    ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.\r\nAdditional potential applications of ctDNA assays, under research development and not recommended for routine practice, include identifying patients not responding to therapy with early dynamic changes in ctDNA levels, monitoring therapy for the development of resistance mutations prior to clinical progression, and in screening asymptomatic people for cancer. Recommendation for reporting of results, future development of ctDNA assays, and future clinical research are made.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#xidmwtbpmi .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#xidmwtbpmi .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#xidmwtbpmi .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#xidmwtbpmi .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#xidmwtbpmi .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#xidmwtbpmi .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#xidmwtbpmi .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#xidmwtbpmi .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#xidmwtbpmi .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#xidmwtbpmi .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#xidmwtbpmi .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#xidmwtbpmi .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#xidmwtbpmi .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#xidmwtbpmi .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#xidmwtbpmi .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#xidmwtbpmi .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#xidmwtbpmi .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#xidmwtbpmi .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#xidmwtbpmi .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#xidmwtbpmi .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#xidmwtbpmi .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#xidmwtbpmi .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#xidmwtbpmi .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#xidmwtbpmi .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#xidmwtbpmi .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#xidmwtbpmi .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#xidmwtbpmi .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#xidmwtbpmi .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#xidmwtbpmi .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#xidmwtbpmi .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#xidmwtbpmi .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#xidmwtbpmi .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#xidmwtbpmi .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#xidmwtbpmi .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#xidmwtbpmi .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood Adv\r\n    Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis.\r\nOur results highlight SA as an attractive outpatient option for R/R PTCL, and their incorporation in the development of upfront treatment paradigms merits urgent consideration. Our results underscore enrollment in clinical trials of SA as a critical strategy for R/R PTCL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInteraction of von Willebrand factor with blood cells in flow models: a systematic review.\r\nThis review might provide a starting point for future research. Extended knowledge on the influence of blood flow on VWF and blood cell interactions can contribute to improved understanding of the variation in bleeding in patients with bleeding disorders.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#goobojozaf .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#goobojozaf .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#goobojozaf .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#goobojozaf .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#goobojozaf .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#goobojozaf .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#goobojozaf .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#goobojozaf .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#goobojozaf .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#goobojozaf .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#goobojozaf .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#goobojozaf .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#goobojozaf .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#goobojozaf .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#goobojozaf .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#goobojozaf .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#goobojozaf .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#goobojozaf .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#goobojozaf .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#goobojozaf .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#goobojozaf .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#goobojozaf .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#goobojozaf .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#goobojozaf .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#goobojozaf .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#goobojozaf .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#goobojozaf .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#goobojozaf .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#goobojozaf .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#goobojozaf .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#goobojozaf .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#goobojozaf .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#goobojozaf .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#goobojozaf .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#goobojozaf .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Developmental changes in iron metabolism and erythropoiesis in mice with human gain-of-function erythropoietin receptor.\r\nIn conclusion, the erythroid drive which initially inhibits hepcidin production in mtHEPOR mice in the prenatal/perinatal period is postnatally abrogated by increasing iron stores promoting hepcidin synthesis. The differences observed in studied characteristics between mtHEPOR heterozygotes and homozygotes suggest dose-dependent alterations of downstream EPOR stimulation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe pleiotropic effects of alpha thalassemia on HbSS and HbSC sickle cell disease: reduced erythrocyte cation co-transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival.\r\nFinally, in a larger cohort we report a median survival of 62yrs in patients with HbSS (n=899) and 80yrs in those with HbSC (n=240). a-thalassemia did not influence survival in HbSS, but a non-significant trend was seen in those with HbSC.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Combined single-cell tracking and omics improves blood stem cell fate regulator identification.\r\nTheir identities, kinship and histories are maintained throughout, massively improving molecular noise filtering and candidate identification. In addition to many identified blood stem CFD regulators, we here provide this pipeline for use also in CFDs other than asymmetric division.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDeveloping a Classification of Hematologic Neoplasms in the Era of Precision Medicine.\r\nA collaborative clinico-pathologic review process will provide a mechanism to update pathologic and genomic criteria within a clinical context. An interactive web-based portal would make the classification more immediately available to the scientific community, while providing accessory features enabling practical application of diagnostic, prognostic, and predictive information.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDiagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel.\r\nThere have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update which includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGrab regulates transferrin receptor recycling and iron uptake in developing erythroblasts.\r\nMechanistically, Grab regulates the exocytosis of Tfrc-associated vesicles by activating the GTPase Rab8, which subsequently promotes the recruitment of the exocyst complex and vesicle exocytosis. Our results reveal a critical role for Grab in regulating the Tf cycle and provide new insights into iron homeostasis and erythropoiesis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImmune landscape after allo-HSCT: TIGIT and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse.\r\nImportantly, we found that high levels of TIGIT and CD161 expression on CD4 T cells at month 3 post-HSCT were distinct features significantly associated with subsequent AML relapse in a second cross sectional cohort. Altogether, these data provide global insights into the immunoregulatory landscape reconstitution following HSCT, and highlight non-canonical inhibitory receptors associated with relapse, which could open the path towards new prognostic tools or therapeutic targets to restore subverted anti-AML immunity.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey.\r\nOverall, although CNB accurately diagnoses lymphoma in most instances, it increases the risk of erroneous or non-definitive conclusions. This large-scale survey also emphasizes the need for systematic expert review in cases of lymphoma suspicion, especially in those sampled by CNB.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNext-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.\r\nOne with progressive disease was treated with lorlatinib and achieved complete response. These data support use of alectinib and lorlatinib as off-label therapeutic options for patients with relapsed or refractory ALK-positive large B-cell lymphoma.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRace, Rituximab, and Relapse in TTP.\r\nBlack patients may require closer monitoring, earlier retreatment, and alternative immunosuppression following rituximab treatment. How race, racism, and the social determinants of health contribute to the disparity in relapse risk in iTTP deserve further study.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors.\r\nSubsequent gene module analyses indicated that gilteritinib responsiveness was associated with lymphocyte differentiation and myeloid leukocyte activation, whereas unresponsiveness to gilteritinib was associated with upregulation of cell-cycle, DNA/RNA metabolic processes, and protein translation. Collectively, these findings indicate a crucial role for microenvironment-mediated factors modulated by BMX in the escape from targeted therapy and have implications for the development of novel therapeutic interventions to restore sensitivity to gilteritinib.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDefective RAB31-mediated megakaryocytic early endosomal trafficking of VWF, EGFR, and M6PR in RUNX1 deficiency.\r\nThere was loss of plasma membrane VWF in RUNX1- and RAB31- deficient megakaryocytic HEL cells, and RHD-iMKs These studies provide evidence that RAB31 is downregulated in RUNX1 haplodeficiency and regulates megakaryocytic vesicle trafficking of 3 major proteins with diverse biological roles. Early endosome defect and impaired vesicle trafficking is a potential mechanism for the -granule defects observed in RUNX1 deficiency.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDifferences in wild type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies.\r\nSupplementing FX into CSA had the effect of dampening FIX-WT activity relative to R338L-FIX activity, suggesting that FX impairs WT tenase formation to a greater extent than R338L-FIX tenase. Our data describe the scale of R338L-FIX assay discrepancies and provide insights into the causative mechanisms that will help establish best practices for the measurement of R338L-FIX activity in patients after gene therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDisparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.\r\nIn summary, Hispanic patients treated on CALGB 10403 did as well as NHWs and better than population estimates. Geographical misalignment between trial sites and disease epidemiology may partially explain the lower-than-expected enrollment of Hispanic AYA ALL patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEfflux Capacity and Aldehyde Dehydrogenase Both Contribute to CD8+ T-cell Resistance to Posttransplant Cyclophosphamide.\r\nYet, MHC-mismatched murine HCT studies revealed that peripherally expanded, phenotypically memory T cells 1-3 months post-transplant originated largely from naÃ¯ve-derived rather than memory-derived T cells surviving PTCy, suggesting that initial resistance and subsequent immune reconstitution are distinct. These studies provide insight into the complex immune mechanisms active in CD8+ T-cell survival, differentiation, and reconstitution after cyclophosphamide, with relevance for post-HCT immune recovery, chemotherapy use in autologous settings, and adoptive cellular therapies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nExtended Duration Letermovir Prophylaxis for Cytomegalovirus Infection after Cord Blood Transplantation in Adults.\r\nLetermovir is highly effective, well tolerated prophylaxis that mitigates CMV infection, CMV-related mortality and antiviral therapy toxicities in CBT recipients. Our data supports prophylaxis duration of at least 6 months after CBT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenomic and microenvironmental landscape of stage I follicular lymphoma, compared to stage III/IV.\r\nThis exploratory study shows that FL stage I is genetically heterogenous with different underlying oncogenic pathways. Stage I FL BCL2trl- is likely STAT6 driven while BCL2trl- stage III/IV appears to be more BCL6trl driven.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHMGA2 expression defines a subset of AML with immature transcriptional signature and vulnerability to G2/M inhibition.\r\nAccordingly, small molecules that target G2/M proteins were preferentially active in vitro and in vivo on HMGA2+ AML specimens. Together, our findings suggest that HMGA2 is a key functional determinant in AML and is associated with stem cell features, G2/M status and related drug sensitivity.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImpaired microtubule dynamics contribute to microthrombocytopenia in RhoB-deficient mice.\r\nOur findings imply that the reduction of this tubulin posttranslational modification results in impaired microtubule dynamics, which might contribute to microthrombocytopenia in RhoB-deficient mice. Importantly, we demonstrate that RhoA and RhoB are localized differently and have selective, non-redundant functions in the megakaryocyte lineage.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIncidence and Predictors of Priapism Events in a Sickle Cell Anemia: A Diary-Based Analysis.\r\nMajor priapism occurred in 9.9% of episodes and was associated with the sum of future priapism events. Men with SCA and at least 3 priapism episodes in the past 12 months are at significant risk for recurrent priapism in the following 3 months.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInflammation accelerates BCR-ABL1+ B-ALL development through upregulation of AID.\r\nThe heat shock protein 90 (Hsp90) inhibitors significantly reduce AID protein level and delay the disease progression of BCR-ABL1+ B-ALL upon inflammatory stimulation. The present data demonstrate the causative role of AID in the development and progression of BCR-ABL1+ B-ALL during inflammation, thus highlighting potential therapeutic targets.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInvariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA.\r\nImportantly, the therapeutic efficacy of a single dose of the CD3/BCMA BsAb was remarkably augmented by restoring iNKT cell activity using adoptive transfer of a-galactosylceramide-loaded DCs. Together, these results reveal iNKT cells as a critical player for the anti-tumor activity of CD3-engaging BsAbs, providing important translational implications.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLow Incidence of Invasive Fungal Disease Following CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Non-Hodgkin Lymphoma.\r\nIFD was rare amongst patients who received CD19 CAR-T therapy for NHL in the absence of routine antifungal prophylaxis despite frequent toxicities including CRS, ICANS, and late neutropenia. This study suggests that in settings with low institutional rates of IFD, routine antifungal prophylaxis may not be indicated.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMiR-146b-5p regulates il-23 receptor complex expression in chronic lymphocytic leukemia cells.\r\nOur findings indicate that IL-12ÃŸ1 expression, a crucial checkpoint for the functioning of the IL-23/IL-23R complex loop, is under the control of miR-146b-5p, which may represent a potential target for therapy since it contributes to the CLL pathogenesis. This trial is registered at as NCT00917540.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNeighborhood disadvantage, health status, and healthcare utilization after blood or marrow transplant: BMTSS report.\r\nIn BMT survivors, access to healthcare and health status are associated with area disadvantage. These findings may inform strategies to address long-term care coordination and retention for vulnerable survivors.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNK cell CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma.\r\nThese results suggest that NK cell exhaustion is already present by the time of myeloma diagnosis and likely contributes to the loss of immunological control of malignant plasma cells. Restoring NK cell function via immune directed therapies offers a route to restoring immunological control in multiple myeloma.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Fusions Associated with Ph-like ALL.\r\nRelapse rate was associated with disease status (P=0.028) and conditioning regimen intensity (P=0.028). In conclusion, our data suggest that alloHCT consolidation results in similarly favorable survival outcomes in adult patients with Ph-like fusions and other high-risk B-cell ALL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReal world study of children and young adults with myeloproliferative neoplasms identifying risks and unmet needs.\r\nRates of thrombotic events and transformation were higher than expected compared with the previous literature. Our study provides new and reliable information as a basis for prospective studies, trials, and development of harmonized international guidelines for the specific management of young patients with MPN.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThird-party CMV- and EBV-specific T cells for first viral reactivation after allogeneic stem cell transplant.\r\nEarly administration of third-party VST in conjunction with antiviral treatment appears safe and leads to excellent viral control and clinical outcomes. Study ID ACTRN12618000343202.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTotal marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide.\r\nFor patients treated with 2000 cGy, with a median follow-up duration of 12.3 months, 1-year relapse/progression, progression-free survival, and overall survival rates were 17%, 74%, and 83%, respectively. In conclusion, HaploHCT-TMLI with PTCy was safe and feasible in our high-risk patient population with promising outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVenetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.\r\nMechanistically, double-hit lymphoma cells subjected to VEN triggered phagocytosis in an apoptosis-independent manner. Our study identifies the combination of VEN and therapeutic antibodies as a promising novel strategy for the treatment of B-cell malignancies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.\r\nThis scoring system was also significantly associated with complete remission, early death and relapse-free survival;  performed similarly in the external validation cohort (n=563) and showed a lower false-positive rate than previously published scores. The European Scoring System =70, easy for routine calculation, predicts long-term survival in older AML patients considered for intensive chemotherapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNext-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.\r\nOur data indicate that anti-CD19 FasT CAR-T shows promising early efficacy for B-ALL. Further evaluations in larger clinical studies are needed.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nTherapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.\r\nThe presence of cytogenetic abnormality and the absence of variants in DNMT3A, TET2, or ASXL1 (DTA-genes) were associated with a higher likelihood of developing a subsequent t-MN and an inferior survival. We describe a putative precursor entity of t-MN with distinct features and outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nCA Cancer J Clin\r\n    Health insurance status and cancer stage at diagnosis and survival in the United States.\r\nPatients without private insurance coverage had worse short-term and long-term survival at each stage for al cancers combined;  patients who were uninsured had worse stage-specific survival for 12 of 17 stageable cancers and had worse survival for leukemia and brain tumors. Expanding access to comprehensive health insurance coverage is crucial for improving access to cancer care and outcomes, including stage at diagnosis and survival.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.\r\nOne-year non-relapse mortality and progression/relapse were 22% and 33% respectively. On multivariate analysis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nExtranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHistological, genetic characterization and follow-up of 130 patients with chronic triplenegative thrombocytosis.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImproved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data.\r\nThe relative benefit associated with CR1 and the relative detriment associated with relapse have decreased over this period;  while achieving CR1 and relapse from CR1 still have strong prognostic associations with outcomes, the magnitude of the association has decreased over time. Possible explanations for these patterns include higher CR rates with salvage therapies after relapse, more frequent use of hematopoietic cell transplant, and better supportive care.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInflammation in WaldenstrÃ¶m macroglobulinemia is associated with 6q deletion and need for treatment initiation.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion.\r\nInstead, we identified a strong association between PDL1 expression and CHL MHC-II expression, TH recruitment, and enrichment of Th1 regulatory cells. These data suggest that a dominant effect of PDL1 expression in CHL may be T helper engagement and promotion of regulatory microenvironment rather than maintenance of exhaustion.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRHOA regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia.\r\nThis elevated IGFBP2 expression is confirmed in primary CML samples. Thus, we demonstrate one mechanism whereby RHOA-SRF-IGFBP2 signaling axis contributes to development of leukemia in cells expressing the p210 BCRABL1 fusion kinase.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis.\r\nThis study suggests that GPD1 may act as a novel tumor suppressor in bladder cancer. Pharmacological activation of GPD1 is a potential therapeutic approach for bladder cancer.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHypertension and incident cardiovascular events after next-generation BTKi therapy initiation.\r\nCollectively, these data suggest that hypertension may be a class effect of BTKi therapies and precedes major cardiotoxic events.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.\r\nTP53 mutations on exons 5, 6 and 7 are predictors of progression and survival. Targeting mutant p53 by APR-246 is a promising therapeutic approach for DLBCL patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia.\r\nFAO or OXPHOS inhibition significantly impeded leukemia progression of Gfi1b-KO MLL/AF9 cells. Finally, we showed that Gfi1b-deficient AML cells were more sensitive to metformin as well as drugs implicated in OXPHOS and FAO inhibition, opening new potential therapeutic strategies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Bleeding propensity in WaldenstrÃ¶m Macroglobulinaemia: Potential causes and evaluation.\r\nIt is thus important to understand the origin of the WM bleeding phenotype to better stratify patients according to their bleeding risk and thus enhance confidence in clinical decisions regarding treatment management. In this review, we detail the evidence for various contributing factors to the bleeding phenotype in WM and focus on current and emerging diagnostic tools that will aid evaluation and management of bleeding in these patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCLEC-2 supports platelet aggregation in mouse but not human blood at arterial shear.\r\nThe reduction in platelet aggregation observed in CLEC1bfl/flGPIb-Cre+ mice during arterial thrombosis is mediated by the loss of CLEC-2 on mouse platelets. In contrast, CLEC-2 does not support thrombus generation on collagen, atherosclerotic plaque or inflamed endothelial cells in human at arterial shear.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDoes Fibrinolytic Strategy of Pulmonary Embolism International THrOmbolysis (PEITHO)-3 Trial Need More Strong Evidence?\r\nMajor cardiovascular guidelines regarding PE have considered full-dose systemic fibrinolysis as Class 3 indication for submassive PE. Various alternative strategies have been designed to reduce bleeding complications without loss of efficacy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#uqwyzwelyf .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#uqwyzwelyf .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#uqwyzwelyf .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#uqwyzwelyf .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#uqwyzwelyf .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#uqwyzwelyf .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#uqwyzwelyf .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#uqwyzwelyf .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#uqwyzwelyf .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#uqwyzwelyf .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#uqwyzwelyf .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#uqwyzwelyf .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#uqwyzwelyf .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#uqwyzwelyf .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#uqwyzwelyf .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#uqwyzwelyf .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#uqwyzwelyf .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#uqwyzwelyf .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#uqwyzwelyf .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#uqwyzwelyf .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#uqwyzwelyf .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#uqwyzwelyf .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#uqwyzwelyf .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#uqwyzwelyf .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#uqwyzwelyf .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#uqwyzwelyf .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#uqwyzwelyf .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#uqwyzwelyf .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#uqwyzwelyf .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#uqwyzwelyf .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#uqwyzwelyf .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#uqwyzwelyf .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#uqwyzwelyf .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#uqwyzwelyf .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#uqwyzwelyf .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis.\r\nExploring the physiological consequences of disease chronicity unique to myelofibrosis, acknowledging the heterogeneity in disease grade, and using advanced prognostic models, molecular diagnostics and other organ function diagnostic tools, we present an innovative review of strategies with the potential to improve transplant outcomes in this disease. Larger, prospective studies which consider the impact of molecular-based disease grade are needed for myelofibrosis transplantation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Antithrombin deficiency: no sugar, no diagnosis!\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAvoiding fratricide: a T-ALL order.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBuckling up against COVID-19 after CAR T-cell therapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGPIIb/IIIa-GPVI-commanded platelet patrol.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIbrutinib frontline in young patients with CLL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIncorporating signaling dynamics into fate decision.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlease eat me! Targeting CD47 and CD38 in T-ALL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRevealing the dark secrets of TP53-mutated AML.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSafety of genetically modified T cells.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe CD19neg needle in the haystack.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.\r\nLastly, as new treatment approaches continue to be explored in CML, this review also discusses the advent of newer therapies such as asciminib. This article may be a useful reference for physicians treating patients with CML with second-generation TKIs and, as it is focused on the physicians' international and personal experiences, may give insight into alternative approaches not previously considered.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRecent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy.\r\nGiven the synergistic effect of VEGFR and other therapies in tumor development and progression, VEGFR dual-target inhibitors are becoming an attractive approach due to their favorable pharmacodynamics, low toxicity, and anti-resistant effects. This perspective provides an overview of the development of VEGFR dual-target inhibitors from multiple aspects, including rational target combinations, drug discovery strategies, structure-activity relationships and future directions.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nReshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.\r\nWe also evaluate the significance of the STIE, TIME, and their interactions as well as changes after local radiotherapy and systemic immunotherapy or combined immunotherapy. We focus our review on the evidence of lung cancer, hepatocellular carcinoma, and nasopharyngeal carcinoma, aiming to reshape STIE and TIME to enhance immunotherapy efficacy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nTargeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.\r\nThis review focused on the discovery, structural modification, preclinical and clinical research of the above compounds from the perspective of medicinal chemistry. Based on this, the possible defects in MDM2 inhibitors in clinical development were analyzed to suggest that the multitarget strategy or targeted degradation strategy based on MDM2 has the potential to reduce the dose-dependent hematological toxicity of MDM2 inhibitors and improve their anti-tumor activity, providing certain guidance for the development of agents targeting the p53-MDM2 interaction.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#auamggkhtj .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#auamggkhtj .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#auamggkhtj .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#auamggkhtj .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#auamggkhtj .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#auamggkhtj .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#auamggkhtj .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#auamggkhtj .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#auamggkhtj .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#auamggkhtj .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#auamggkhtj .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#auamggkhtj .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#auamggkhtj .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#auamggkhtj .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#auamggkhtj .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#auamggkhtj .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#auamggkhtj .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#auamggkhtj .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#auamggkhtj .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#auamggkhtj .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#auamggkhtj .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#auamggkhtj .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#auamggkhtj .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#auamggkhtj .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#auamggkhtj .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#auamggkhtj .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#auamggkhtj .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#auamggkhtj .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#auamggkhtj .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#auamggkhtj .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#auamggkhtj .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#auamggkhtj .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#auamggkhtj .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#auamggkhtj .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#auamggkhtj .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Does Fetal Hemoglobin inhibit the malarial parasite Plasmodium falciparum?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEarly hydroxyurea use is neuroprotective in children with sickle cell anemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHLA-matched related-donor hematopoietic stem cell transplantation is a suitable treatment in adolescents and adults with sickle cell disease: comparison of myeloablative and non-myeloablative approaches.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcome prediction by the knowledge bank approach in AML patients undergoing allogeneic stem cell transplantation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSpace anemia unexplained: red blood cells seem to be space-proof.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe association of iron deficiency anemia, thrombocytosis at delivery and postpartum venous thromboembolism.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Risk-adapted modulation through de-intensification of cancer treatments: An ESMO classification.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nG-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nJ Hematol Oncol\r\n    First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia.\r\nNotably, CLL-1 is also highly expressed in normal granulocytes, so bridging hematopoietic stem cell transplantation (HSCT) may be a viable strategy to rescue long-term agranulocytosis due to off-target toxicity. In conclusion, this study is the first to demonstrate the positive efficacy and tolerable safety of CLL-1 CAR-T cell therapy in adult R/R AML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\n\r\n\r\n\r\nOthers\r\nall remaining publications eg case reports, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#vmkityvgar .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#vmkityvgar .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vmkityvgar .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#vmkityvgar .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#vmkityvgar .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#vmkityvgar .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vmkityvgar .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#vmkityvgar .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#vmkityvgar .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#vmkityvgar .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#vmkityvgar .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#vmkityvgar .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#vmkityvgar .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#vmkityvgar .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#vmkityvgar .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#vmkityvgar .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#vmkityvgar .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#vmkityvgar .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#vmkityvgar .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#vmkityvgar .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#vmkityvgar .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#vmkityvgar .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#vmkityvgar .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#vmkityvgar .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vmkityvgar .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#vmkityvgar .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vmkityvgar .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#vmkityvgar .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#vmkityvgar .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#vmkityvgar .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#vmkityvgar .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#vmkityvgar .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#vmkityvgar .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#vmkityvgar .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#vmkityvgar .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    An unexpected finding during microscopy for urinary hemosiderin.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHuman Papilloma Virus Vaccine and VITT antibody induction.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInsane in the membrane: A case of hereditary spherocytic pyropoikilocytosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPeripheral CD5+ CD10+ B-cell proliferation with atypical morphology attributable to human herpesvirus 6 infection following umbilical cord blood transplantation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    A unique report of breast intravascular NK/T-cell lymphoma mimicking breast carcinoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDrug-associated immune thrombocytopenia: An updated list of suspected drugs based on the WHO pharmacovigilance database.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLonger-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSecondary AML with MLL gene amplification.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nChronic inflammation persistence after regular blood transfusion therapy in sickle cell anemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCombined BCL2 and BTK Inhibition in CLL Demonstrates Efficacy after Monotherapy with Both Classes.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHematologist Encounters Among Medicaid Patients who have Sickle Cell Disease.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLiver Fibrosis and its Response to Avapritinib in 2 Patients with Systemic Mastocytosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLow rate of subsequent malignant neoplasms following CAR T-cell therapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrimary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSexual violence as a precipitator of chronic pain in young adults with sickle cell disease.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe Dosing of Ibrutinib and Related Bruton's Tyrosine Kinase Inhibitors: Eliminating the Use of Brute Force.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    Breast cancer survivors face greater cardiometabolic risks.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNew studies examine COVID-19 risks among cancer patients.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-07-17T12:06:47-04:00",
    "input_file": {}
  }
]
